Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy

Area of Science:

• Oncology
• Systems Biology
• Computational Biology

Background:

• Targeted cancer drugs inhibit oncogenes but frequently encounter drug resistance.
• Cancer cells adapt to targeted therapies by rewiring complex signaling networks.
• This adaptive resistance limits the long-term efficacy of many cancer treatments.

Purpose of the Study:

• To identify a combinatorial drug target that can overcome adaptive resistance to targeted cancer therapies.
• To develop and apply a computational framework for analyzing cancer signaling networks and predicting effective drug combinations.
• To discover novel therapeutic strategies for colorectal cancer that circumvent resistance mechanisms.

Main Methods:

• Developed a Boolean network simulation and analysis framework.
• Applied the framework to a large-scale colorectal cancer signaling network.
• Integrated genomic information to model cancer cell adaptive responses.
• Identified critical nodes and feedback regulations within the network.

Main Results:

• Discovered Src as a critical combination drug target.
• Demonstrated that targeting Src can overcome adaptive resistance to mitogen-activated protein kinase pathway inhibitors.
• Identified Src's role in blocking essential feedback regulation responsible for resistance.
• Validated the framework's ability to predict effective combinatorial targets.

Conclusions:

• Src is a promising target for overcoming adaptive resistance in colorectal cancer.
• Combinatorial targeting strategies involving Src can enhance the efficacy of existing targeted therapies.
• The developed Boolean network framework is a versatile tool for identifying resistance-breaking drug targets across various cancers.
• This approach offers a pathway to more durable and effective cancer treatments.